Bristol-Myers Squibb And UCLA Enter Into A Collaboration Agreement As Part Of U.S. Immuno-Oncology Rare Population Malignancy Research Program

Monday, December 14, 2015


Bristol-Myers Squibb Company (NYSE:BMY) today announced that they have entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

View All News »